TABLE 2.

HPV Vaccine Coverage Among Patients Aged 11 or 12 Years, 3- and 6-Month Posttraining (n = 17 173).

	3-Months Posttraining				6-Months Posttraining
	Coverage at 3 Mo (%)a	Coverage Change Over Previous 3 Mo (%)b	Difference From Control (%) (95% CI)b	P	Coverage at 6 Mo (%)a	Coverage Change Over Previous 6 Mo (%)b	Difference From Control (%) (95% CI)b	P
≥1 dose
Control	37.3	6.4	Reference	—	41.2	9.5	Reference	—
Announcement	38.0	11.5	5.1 (2.0 to 8.2)	.003*	42.0	14.9	5.4 (1.1 to 9.7)	.02*
Conversation	30.3	8.4	2.0 (–0.4 to 4.4)	.10	33.7	11.5	2.0 (–1.4 to 5.5)	.24
≥1 dose to girls
Control	39.6	7.2	Reference	—	44.0	11.2	Reference	—
Announcement	41.0	12.0	4.8 (1.6 to 8.0)	.004*	45.2	15.7	4.6 (0.1 to 9.0)	.045*
Conversation	33.0	8.8	1.5 (–0.9 to 4.0)	.21	36.4	11.9	0.7 (–2.9 to 4.3)	.69
≥1 dose, boys
Control	35.7	6.0	Reference	–	39.2	8.4	Reference	—
Announcement	35.8	11.6	5.6 (2.0 to 9.1)	.003*	39.7	14.7	6.2 (1.5 to 11.0)	.01*
Conversation	28.3	8.1	2.1 (–0.5 to 4.8)	.11	31.9	11.3	2.8 (–0.9 to 6.6)	.13
3 doses
Control	11.5	1.9	Reference	—	13.5	3.6	Reference	—
Announcement	9.2	2.6	0.7 (–0.7 to 2.1)	.32	10.7	3.9	0.3 (–1.8 to 2.3)	.81
Conversation	7.2	1.5	−0.4 (–1.4 to 0.7)	.48	9.2	3.3	−0.3 (–2.1 to 1.5)	.71
3 doses, girls
Control	12.6	2.1	Reference	—	14.7	4.0	Reference	—
Announcement	11.1	3.0	0.9 (–0.5 to 2.4)	.21	12.9	4.3	0.3 (–1.9 to 2.4)	.81
Conversation	8.9	2.0	0.0 (–1.1 to 1.1)	.97	11.0	4.0	0.0 (–2.0 to 1.9)	.97
3 doses, boys
Control	10.6	1.8	Reference	—	12.5	3.3	Reference	—
Announcement	7.5	2.1	0.3 (–1.3 to 1.8)	.70	8.8	3.4	0.1 (–2.3 to 2.4)	.96
Conversation	5.9	1.2	−0.6 (–1.8 to 0.6)	.28	7.6	2.7	−0.6 (–2.6 to 1.4)	.55

^aVaccine coverage is unadjusted.

^bThree- and 6-month coverage change and comparisons among trial arms are adjusted for clustering at the clinic level.

^*P < .05.